Experience

Bioscience Institute

• San Marino
• Biotechnology Research
• 1 - 100 Employee

• Biotechnologist

  • ‏مايو 2016 - - الحالي



Fondazione IRCCS Istituto Nazionale Tumori Milano

• Postdoctoral fellow Fondazione Umberto Veronesi

  • ‏يناير 2016 - ‏مايو 2016

  Preclinically development of novel therapeutic strategies for TNBC based on the inhibition of survivin expression/functions.Objective of the study will be the evaluation of the antitumor effect exerted by the reconstitution of two microRNAs found to be involved in the regulation of survivin expression and downregulated in breast cancer in TNBC cell models and their ability to improve the response to chemo-therapeutic agents and ionizing radiation. Preclinically development of novel therapeutic strategies for TNBC based on the inhibition of survivin expression/functions.Objective of the study will be the evaluation of the antitumor effect exerted by the reconstitution of two microRNAs found to be involved in the regulation of survivin expression and downregulated in breast cancer in TNBC cell models and their ability to improve the response to chemo-therapeutic agents and ionizing radiation.



Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

• Italy
• Hospitals and Health Care
• 700 & Above Employee

• PostDoctoral Researcher

  • ‏مارس 2012 - ‏أبريل 2016

  Involved in a project addressing the role of Ret oncoproteins in the regulation of survival/death pathways in tumor cells. Specifically, the objective of my studies is the elucidation of the molecular determinants involved in apoptosis and autophagy induction by Ret inhibitors currently under clinical investigation in thyroid cancer. Focusing, in particular, the role of the dependence receptor function of the Ret receptor, and its relationship with the extrinsic apoptosis pathway.Currently involved in the identification of new therapeutic strategies for the treatment of human triple-negative breast cancer cells. Specifically, I recently collaborated to a project aimed at assessing the capability of YM155 –a selective survivin suppressant- to enhance TRAIL-induced apoptosis in TNBC cells.

• PhD Student

  • ‏سبتمبر 2011 - ‏مارس 2012



The Wistar Institute

• United States
• Research Services
• 200 - 300 Employee

• Visiting Scientist

  • ‏سبتمبر 2010 - ‏سبتمبر 2011

  PhD Student in Biotechnologies applied to Medical SciencesCharacterization of a survivin alternative splicing, DEx3 PhD Student in Biotechnologies applied to Medical SciencesCharacterization of a survivin alternative splicing, DEx3



UMass Chan Medical School

• United States
• Higher Education
• 700 & Above Employee

• Fellow

  • ‏أكتوبر 2009 - ‏سبتمبر 2010

  PhD Student in Biotechnologies applied to Medical SciencesCharacterization of a survivin alternative splicing, DEx3 PhD Student in Biotechnologies applied to Medical SciencesCharacterization of a survivin alternative splicing, DEx3



Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

• Italy
• Hospitals and Health Care
• 700 & Above Employee

• Fellow

  • ‏يوليو 2007 - ‏أكتوبر 2009

  Projects focused on the development of antisense-based approaches aimed at interfering with the expression and function of members of the Inhibitors of Apoptosis Protein (IAP) family such as survivin and Apollon/BRUCE in human tumour models as well as on the evaluation of anticancer effects of structurally novel inhibitors of Hsp90 chaperone function (such as AICAR) in cancer cells

• Ungraduate Student

  • ‏أكتوبر 2004 - ‏يوليو 2007

  Internship to pursue medical biotechnologies degree, Dept. Experimental Oncology & Molecular Medicine Molecular Pharmacology Unit.Title of thesis: Rational identificantion of the non-peptidic small molecule 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) as a structurally novel inhibitor of HSP90 chaperone function in cancer cells